In brief: BresaGen, Premier Bionics, Panbio, Eqitx
Friday, 03 February, 2006
BresaGen has concluded an agreement with Indian firm BV BioCorp, to register and distribute BresaGen's G-CSF for leukaemia and an undisclosed product in India, Sri Lanka, Bangladesh, and Nepal. Details of the agreement are confidential, but BresaGen anticipates the projects will be developed and clinical trials for registration will commence in early 2007.
Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI) has signed a contract with German company VR Magic for the sale and distribution of the Eyesis Ophthalmossurgical Simulator, which provides training for vitreo-retinal and cataract surgery, in Australia and New Zealand with rights to sell into the Asia Pacific region.
Panbio (ASX:PBO) has appointed Peter Arnison, a former governor of Queensland, as the company's new chairman.
Dr Nick Ede has resigned from his position as chief operating officer and general manager of Eqitx (ASX:EQX) subsidiary ZingoTX to pursue other career options.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
